No Data
No Data
AHF: Global HIV Response Demands Broader Lenacapavir Access
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Express News | RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75
Gilead Sciences Analyst Ratings
Wells Fargo's 'Value Equity' Stocks: VZ, AZO, KR, and More
Express News | Gilead Donates Remdesivir for Emergency Use in Response to Marburg Virus Disease in Rwanda